Skip to content

The effectiveness of hyaluronidase injections in treating trigger finger

Comparison of the Effectiveness of Hyaluronidase versus Corticosteroid Injection in the Treatment of Patients with Trigger Finger: A Randomized, Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20260201068732N1
Enrollment
46
Registered
2026-05-11
Start date
2026-04-21
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigger finger. Trigger finger

Interventions

Intervention 1: Intervention group: Injection of Lidocaine 2% local anesthesia and 1500 U hyalase is performed. Intervention 2: Control group: Injection of Lidocaine 2% local anesthesia and 1 mililite

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Trigger finger diagnosis according to clinical criteria by a specialist Duration of diagnosis at least 3 months Unilateral or bilateral trigger finger Neutral metacarpophalangeal joint position can be achieved during passive isolated metacarpophalangeal joint extension of the affected finger Grade 1-3 (Based on the latest edition of the Comprehensive Reference of Physical Medicine, the classification of this condition includes: Type 0: mild cryptorchidism in the finger, Type 1: inadequate movement in one finger, Type 2: correctable with active movement, Type 3: correctable with passive movement, Type 4: fixed and uncorrectable deformity)

Exclusion criteria

Exclusion criteria: Similar injection in the past 3 months Platelets below 50,000 Uncontrolled hyperthyroidism Glucose-6-phosphate dehydrogenase deficiency (favism) Allergic reactions to corticosteroids or hyalase Coagulopathy Pregnancy Sensory disturbances, scarring, edema in the trigger finger

Design outcomes

Primary

MeasureTime frame
Pain score. Timepoint: First visit, and weeks 4 and 12 after intervention. Method of measurement: Visual Analogue Scale (VAS).

Secondary

MeasureTime frame
Movement Disability. Timepoint: First visit and weeks 4 and 12 after injection. Method of measurement: Physical examination and Quick-DASH checklist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNikta Nikbakht

Hamedan University of Medical Sciences

m.a.soh93@gmail.com+98 81 3131 4058

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026